See the published version of this article at BMC Pulmonary Medicine.
This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research article
Prognostic value of pretreatment platelet counts in lung cancer: a systematic review and meta-analysis
Ying Ying Qian
Nanjing First Hospital
Corresponding Author
License:
This work is licensed under a CC BY 4.0 License. Read Full License
View the published version at BMC Pulmonary Medicine.
Background : The prognostic value of elevated pretreatment platelet counts remains controversial in lung cancer patients. We performed the present meta-analysis to determine its precise role in these patients.
Methods: We employed a multiple search strategy in the PubMed, EMBASE and Cochrane Library databases to identify eligible studies. Disease-free survival (DFS)/progression-free survival (PFS)/time to progression (TTP) and overall survival (OS) were used as outcomes with hazard ratios (HRs) and 95% confidence intervals (CIs). Heterogeneity among the studies and publication bias were also evaluated.
Results : A total of 40 studies including 16696 lung cancer patients were eligible for the analysis. Overall, the pooled analysis showed that compared with normal platelet counts, elevated pretreatment platelet counts were associated with poorer OS (HR= 1.54, 95% CI: 1.37-1.72, P<0.001) and poorer DFS/PFS/TTP (HR=1.62, 95% CI: 1.33-1.98, P<0.001) in patients with lung cancer. In subgroup analyses, elevated pretreatment platelet counts were also associated with poorer OS and DFS/PFS/TTP in most subgroups. There was no evidence of publication bias.
Conclusions : This meta-analysis revealed that elevated pretreatment platelet counts were an independent predictor of OS and DFS/PFS/TTP in lung cancer patients. Large-scale prospective studies and a validation study are warranted.
Keywords
lung cancer, platelet count, prognosis, meta-analysis
Figure 1
Figure 2
Figure 3
Figure 4
This is a list of supplementary files associated with this preprint. Click to download.
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Published
Version 5
Posted 13 Apr, 2020
Published
On 20 Apr, 2020
No community comments so far
Editorial decision: Accept
On 06 Apr, 2020
No comments provided
Editorial decision: Minor revision
On 04 Apr, 2020
Editor assigned
On 03 Apr, 2020
Submission checks complete
On 02 Apr, 2020
Editor invited
On 02 Apr, 2020
No comments provided
Reviewer #2 agreed
On 26 Mar, 2020
Review #2 received
Received 26 Mar, 2020
Editorial decision: Minor revision
On 26 Mar, 2020
Reviewers invited
Invitations sent on 20 Mar, 2020
Reviewer #1 agreed
On 20 Mar, 2020
Review #1 received
Received 20 Mar, 2020
Editor assigned
On 16 Mar, 2020
Editor invited
On 15 Mar, 2020
Submission checks complete
On 13 Mar, 2020
No comments provided
Editorial decision: Major revision
On 24 Feb, 2020
Reviewer #2 agreed
On 19 Feb, 2020
Reviewer #3 agreed
On 19 Feb, 2020
Review #2 received
Received 19 Feb, 2020
Review #3 received
Received 19 Feb, 2020
Editor assigned
On 18 Feb, 2020
Reviewers invited
Invitations sent on 18 Feb, 2020
Reviewer #1 agreed
On 18 Feb, 2020
Review #1 received
Received 18 Feb, 2020
Submission checks complete
On 17 Feb, 2020
Editor invited
On 17 Feb, 2020
No comments provided
Editorial decision: Major revision
On 23 Jan, 2020
Review #3 received
Received 22 Jan, 2020
Review #2 received
Received 20 Jan, 2020
Reviewer #3 agreed
On 11 Jan, 2020
Reviewer #2 agreed
On 08 Jan, 2020
Review #1 received
Received 08 Dec, 2019
Reviewer #1 agreed
On 08 Dec, 2019
Reviewers invited
Invitations sent on 05 Dec, 2019
Submission checks complete
On 23 Oct, 2019
Editor assigned
On 17 Oct, 2019
First submitted
On 16 Oct, 2019
Editor invited
On 16 Oct, 2019
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Learn more about our company.
This preprint is under consideration at BMC Pulmonary Medicine. A preprint is a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research article
Prognostic value of pretreatment platelet counts in lung cancer: a systematic review and meta-analysis
Ying Ying Qian
Nanjing First Hospital
Corresponding Author
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Published
Version 5
Posted 13 Apr, 2020
Published
On 20 Apr, 2020
No community comments so far
Editorial decision: Accept
On 06 Apr, 2020
No comments provided
Editorial decision: Minor revision
On 04 Apr, 2020
Editor assigned
On 03 Apr, 2020
Submission checks complete
On 02 Apr, 2020
Editor invited
On 02 Apr, 2020
No comments provided
Reviewer #2 agreed
On 26 Mar, 2020
Review #2 received
Received 26 Mar, 2020
Editorial decision: Minor revision
On 26 Mar, 2020
Reviewers invited
Invitations sent on 20 Mar, 2020
Reviewer #1 agreed
On 20 Mar, 2020
Review #1 received
Received 20 Mar, 2020
Editor assigned
On 16 Mar, 2020
Editor invited
On 15 Mar, 2020
Submission checks complete
On 13 Mar, 2020
No comments provided
Editorial decision: Major revision
On 24 Feb, 2020
Reviewer #2 agreed
On 19 Feb, 2020
Reviewer #3 agreed
On 19 Feb, 2020
Review #2 received
Received 19 Feb, 2020
Review #3 received
Received 19 Feb, 2020
Editor assigned
On 18 Feb, 2020
Reviewers invited
Invitations sent on 18 Feb, 2020
Reviewer #1 agreed
On 18 Feb, 2020
Review #1 received
Received 18 Feb, 2020
Submission checks complete
On 17 Feb, 2020
Editor invited
On 17 Feb, 2020
No comments provided
Editorial decision: Major revision
On 23 Jan, 2020
Review #3 received
Received 22 Jan, 2020
Review #2 received
Received 20 Jan, 2020
Reviewer #3 agreed
On 11 Jan, 2020
Reviewer #2 agreed
On 08 Jan, 2020
Review #1 received
Received 08 Dec, 2019
Reviewer #1 agreed
On 08 Dec, 2019
Reviewers invited
Invitations sent on 05 Dec, 2019
Submission checks complete
On 23 Oct, 2019
Editor assigned
On 17 Oct, 2019
First submitted
On 16 Oct, 2019
Editor invited
On 16 Oct, 2019
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
License:
This work is licensed under a CC BY 4.0 License. Read Full License
View the published version at BMC Pulmonary Medicine.
Background : The prognostic value of elevated pretreatment platelet counts remains controversial in lung cancer patients. We performed the present meta-analysis to determine its precise role in these patients.
Methods: We employed a multiple search strategy in the PubMed, EMBASE and Cochrane Library databases to identify eligible studies. Disease-free survival (DFS)/progression-free survival (PFS)/time to progression (TTP) and overall survival (OS) were used as outcomes with hazard ratios (HRs) and 95% confidence intervals (CIs). Heterogeneity among the studies and publication bias were also evaluated.
Results : A total of 40 studies including 16696 lung cancer patients were eligible for the analysis. Overall, the pooled analysis showed that compared with normal platelet counts, elevated pretreatment platelet counts were associated with poorer OS (HR= 1.54, 95% CI: 1.37-1.72, P<0.001) and poorer DFS/PFS/TTP (HR=1.62, 95% CI: 1.33-1.98, P<0.001) in patients with lung cancer. In subgroup analyses, elevated pretreatment platelet counts were also associated with poorer OS and DFS/PFS/TTP in most subgroups. There was no evidence of publication bias.
Conclusions : This meta-analysis revealed that elevated pretreatment platelet counts were an independent predictor of OS and DFS/PFS/TTP in lung cancer patients. Large-scale prospective studies and a validation study are warranted.
Figure 1
Figure 2
Figure 3
Figure 4